How do you pay?

How to pay the least

Ask for the cash price

Phyrago

Sold only in a different form, strength or formula. Switching to one would need a new prescription, so ask your prescriber whether it could work for you.

  1. Ask your pharmacy for Phyrago’s cash price, and one or two other pharmacies too.
  2. Phyrago’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand namePhyrago
Authorized genericdasatinib
Regular genericdasatinib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Other forms onlyAsk your doctor
Same as Phyrago?
The original
–
–

Brand nameThe maker’s card

Cycle Vita Co-Pay Assistance Program

Savings card from Cycle Pharmaceuticals

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a prescription

Sign up on phyrago.com 

See the offer on phyrago.com

In the maker’s words

“Commercially insured eligible patients may pay as little as $0.”

From the maker’s offer on phyrago.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Phyrago itself, from the same company, sold without the brand name, and usually for less. For now Phyrago is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Sold only in a different form, strength or formula. Switching to one would need a new prescription, so ask your prescriber whether it could work for you. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

PHYRAGOTM is a kinase inhibitor indicated for the treatment of

  • newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
  • adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.
  • adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
  • pediatric patients 1 year of age and older with Ph+ CML in chronic phase.
  • pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.

Source: the FDA label for Phyrago (Cycle Pharmaceuticals Ltd), August 23, 2025. Full label on DailyMed 

Good to know